IRIS
RIVARA, Silvia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.301
AS - Asia 4.947
EU - Europa 4.824
SA - Sud America 810
AF - Africa 252
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 17.140
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.122
SG - Singapore 2.095
CN - Cina 1.631
IT - Italia 1.006
FI - Finlandia 784
IE - Irlanda 687
BR - Brasile 655
SE - Svezia 654
DE - Germania 498
HK - Hong Kong 411
UA - Ucraina 332
VN - Vietnam 303
NL - Olanda 204
ZA - Sudafrica 166
TR - Turchia 162
GB - Regno Unito 153
CA - Canada 115
RU - Federazione Russa 109
FR - Francia 91
IN - India 80
AT - Austria 79
BE - Belgio 63
AR - Argentina 62
CI - Costa d'Avorio 51
MX - Messico 42
PL - Polonia 42
BD - Bangladesh 38
JP - Giappone 38
ID - Indonesia 37
ES - Italia 36
KR - Corea 30
CZ - Repubblica Ceca 26
EC - Ecuador 24
IQ - Iraq 23
PK - Pakistan 20
VE - Venezuela 17
CO - Colombia 13
JO - Giordania 13
MA - Marocco 11
PY - Paraguay 10
LT - Lituania 9
CL - Cile 8
EG - Egitto 8
PE - Perù 8
UZ - Uzbekistan 8
RO - Romania 7
AE - Emirati Arabi Uniti 6
KE - Kenya 6
UY - Uruguay 6
AZ - Azerbaigian 5
BO - Bolivia 5
DO - Repubblica Dominicana 5
HN - Honduras 5
IL - Israele 5
NP - Nepal 5
SA - Arabia Saudita 5
AL - Albania 4
EE - Estonia 4
PS - Palestinian Territory 4
RS - Serbia 4
TH - Thailandia 4
BY - Bielorussia 3
CY - Cipro 3
HR - Croazia 3
HU - Ungheria 3
LB - Libano 3
MD - Moldavia 3
NI - Nicaragua 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
AM - Armenia 2
BG - Bulgaria 2
BH - Bahrain 2
CR - Costa Rica 2
ET - Etiopia 2
GY - Guiana 2
JM - Giamaica 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LU - Lussemburgo 2
LV - Lettonia 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
PH - Filippine 2
PT - Portogallo 2
SY - Repubblica araba siriana 2
AO - Angola 1
BB - Barbados 1
BW - Botswana 1
CH - Svizzera 1
DK - Danimarca 1
DZ - Algeria 1
EU - Europa 1
GR - Grecia 1
IR - Iran 1
MK - Macedonia 1
MY - Malesia 1
NG - Nigeria 1
Totale 17.130
Salva come PNG Salva come JPEG
Città #
Singapore 1.066
Ashburn 776
Chandler 711
Dublin 685
Dallas 592
Santa Clara 415
Beijing 411
Hong Kong 408
Jacksonville 383
Ann Arbor 350
Parma 332
Dearborn 270
Boardman 235
Nanjing 182
Johannesburg 153
Los Angeles 140
New York 139
Izmir 135
Princeton 135
Munich 134
Shanghai 125
Ho Chi Minh City 112
Hefei 109
Wilmington 103
San Mateo 86
Helsinki 71
Bremen 69
Columbus 68
Hanoi 67
Vienna 65
Toronto 63
Brussels 59
São Paulo 56
Shenyang 55
Moscow 54
Abidjan 51
Bologna 49
Hebei 48
Kunming 47
Nanchang 46
Jinan 45
Buffalo 43
The Dalles 41
Turku 41
Düsseldorf 40
Milan 38
Tokyo 38
Council Bluffs 37
Guangzhou 36
London 34
Changsha 31
Warsaw 31
Woodbridge 31
Frankfurt am Main 30
Modena 30
Seattle 30
Des Moines 29
Jiaxing 29
Jakarta 28
Seoul 28
Brescia 27
Houston 25
San Jose 24
Chennai 23
Montreal 23
Pune 23
Phoenix 22
Stockholm 22
Tianjin 22
Brooklyn 20
Fremont 20
Rio de Janeiro 20
Belo Horizonte 19
Nuremberg 19
Ankara 18
Amsterdam 17
Zhengzhou 17
Norwalk 16
Chicago 15
Denver 15
Hangzhou 15
Da Nang 14
Dong Ket 14
Paris 14
Atlanta 13
Auburn Hills 13
Brno 13
Haiphong 13
Amman 12
San Francisco 12
Brasília 11
Mexico City 11
Poplar 11
Boston 10
Campinas 10
Fuzhou 10
Grafing 10
Naples 10
Orem 10
Ottawa 10
Totale 10.388
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 313
Benzisothiazolinone Derivatives as Potent Allosteric Monoacylglycerol Lipase Inhibitors That Functionally Mimic Sulfenylation of Regulatory Cysteines 239
Antidepressant-like activity and cardioprotective effects of fatty acid amide hydrolase inhibitor URB694 in socially stressed Wistar Kyoto rats 204
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 199
2-Aminobenzimidazoles as new potent H3-antagonists 197
Analysis of Structure-Activity Relationships for MT2 Selective Antagonists by Melatonin MT1 and MT2 Receptor Models 196
New Antimicrobials Targeting Bacterial RNA Polymerase Holoenzyme Assembly Identified with an in Vivo BRET-Based Discovery Platform 195
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 192
Antidepressant-like effects of pharmacological inhibition of FAAH activity in socially isolated female rats 192
Social stress-induced depressive-like symptoms and changes in gut microbial and lipidomic profiles are prevented by pharmacological inhibition of FAAH activity in male rats 190
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 188
Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma 187
2-N-Acylaminoalkylindoles: Design and Quantitative Structure-Activity Relationship Studies Leading to MT2-Selective Melatonin Antagonists 181
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 180
Amino acid derivatives as palmitoylethanolamide prodrugs: Synthesis, in vitro metabolism and in vivo plasma profile in rats 173
Aminobenzimidazoles as new potent H3-antagonists 172
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 168
Application of 3D-QSAR in the Rational Design of Receptor Ligands and Enzyme Inhibitors 166
Cardioprotective effects of fatty acid amide hydrolase inhibitor URB694, in a rodent model of trait anxiety 164
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 163
Synthesis, biological activity, QSAR and QSPR study of 2/aminobenzimidazole derivatives as potent H3-antagonists 162
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 160
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 160
Alchilammidi tricicliche: ligandi selettivi dei recettori melatoninergici MT1 e MT2 159
Free-Energy Simulations Support a Lipophilic Binding Route for Melatonin Receptors 158
Chiral Recognition of Flexible Melatonin Receptor Ligands Induced by Conformational Equilibria 157
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability 155
N-Acylethanolamine Acid Amidase (NAAA): Mechanism of Palmitoylethanolamide Hydrolysis Revealed by Mechanistic Simulations 152
The Role of HB-Donor Groups in the Heterocyclic Polar Fragment of H3-Antagonists. I. Synthesis and Biological Assays 151
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 149
Validation of a histamine H3 receptor model through structure–activity relationships for classical H3 antagonists 147
Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs 146
Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors 146
Discovery of novel FGF trap small molecules endowed with anti-myeloma activity 142
Dibasic non-imidazole histamine H3 receptor antagonists with a rigid byphenyl scaffold. 142
Chapter 9: Natural and Synthetic Agents That Target Intracellular Monoacylglycerol Lipase (MGL) Activity 139
Small molecules targeting the eubacterial β-sliding clamp discovered by combined in silico and in vitro screening approaches 138
QSAR study of 2-aminobenzimidazole derivatives as H3 antagonists 137
Synthesis and 3D-QSAR Analysis of H3 Receptor Antagonists Containing a Neutral Heterocyclic Polar Group 135
N-(Anilinoethyl)amide Melatonergic Ligands with Improved Water Solubility and Metabolic Stability 133
Cyclohexylcarbamic Acid 3'- or 4'-Substituted Biphenyl-3-yl Esters of as Fatty Acid Amide Hydrolase Inhibitors: Synthesis, Quantitative Structure-Activity Relationships and Molecular Modelling Studies 131
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 131
Toward the Definition of Stereochemical Requirements for MT(2)-Selective Antagonists and Partial Agonists by Studying 4-Phenyl-2-propionamidotetralin Derivatives. 130
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 130
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 129
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 128
Development of a GPCR model for SAR interpretation of classical and new H3 antagonists 127
Experimental and Theoretical Analysis of the Interaction of (±)-cis-Ketoconazole with b-Cyclodextrin in the presence of (+)-L-Tartaric Acid 125
APPLICATION OF COMPUTATIONAL METHODSTO THE DESIGN OF FATTY ACID AMIDE HYDROLASE(FAAH) INHIBITORS BASED ON A CARBAMICTEMPLATE STRUCTURE 125
N-(Anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands 123
2-Arylmelatonin analogues: Probing the 2-phenyl binding pocket of melatonin MT1 and MT2 receptors 123
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 121
MT2 selective melatonin receptor antagonists: design and structure-activity relationships 120
Synthesis and biological assays of new H3-antagonists with imidazole and imidazoline polar groups 120
Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity 119
Anxiolytic effects of the melatonin MT2 receptor partial agonist UCM765: Comparison with melatonin and diazepam. 119
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 119
Pharmacokinetics, pharmacodynamics and safety studies on URB937, a peripherally restricted fatty acid amide hydrolase inhibitor, in rats 118
Synthesis, Enantiomeric Resolution, and Structure-Activity Relationship Study of a Series of 10,11-Dihydro-5H-Dibenzo[a,d]cycloheptene MT(2) Receptor Antagonists. 116
Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity. 116
N-(2-Oxo-3-oxetanyl)carbamic Acid Esters as N-Acylethanolamine Acid Amidase Inhibitors: Synthesis, Structure–Activity and Structure–Property Relationships. 116
JAK3 Inhibitors: Covalent and Noncovalent Interactions of a Cyanamide Group Investigated by Multiscale Free-Energy Simulations 115
Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands. 115
Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors 115
Metadynamics Simulations Distinguish Short- and Long-Residence-Time Inhibitors of Cyclin-Dependent Kinase 8. 115
Social stress contagion in rats: Behavioural, autonomic and neuroendocrine correlates 114
Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations 114
Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents 114
An Optimized Workflow for the Discovery of New Antimicrobial Compounds Targeting Bacterial RNA Polymerase Complex Formation 113
Identification of bivalent ligands with melatonin receptor agonist and fatty acid amide hydrolase (FAAH) inhibitory activity that exhibit ocular hypotensive effect in the rabbit 113
Tricyclic Alkylamides as Melatonin Receptor Ligands with Antagonist or Inverse Agonist Activity 113
Free-energy studies reveal a possible mechanism for oxidation-dependent inhibition of MGL 112
Mechanistic Modeling of Monoglyceride Lipase Covalent Modification Elucidates the Role of Leaving Group Expulsion and Discriminates Inhibitors with High and Low Potency 110
Tetrahydroquinoline Ring as a Versatile Bioisostere of Tetralin for Melatonin Receptor Ligands 110
2-[N-Acylamino(C1-C3)alkyl]indoles as MT1 Melatonin Receptor Partial Agonists, Antagonists, and Putative Inverse Agonists. 109
Histamine H3-antagonists: the basicity of the polar group in quantitative structure-activity and structure-property relationship 108
Synthesis, Pharmacological Evaluation and Structure-Activity Relationships of Benzopyran Derivatives with Potent SERM Activity 107
New classes of potent heparanase inhibitors from ligand-based virtual screening 107
Plasma concentration and brain penetration of the H3-receptor antagonist Thioperamide in rats 106
Three-Dimensional Quantitative Structure-Activity Relationship Studies on Selected MT1 and MT2 Melatonin Receptor Ligands: Requirements for Subtype Selectivity and Intrinsic Activity Modulation 106
Synthesis and biological evaluation of new non-imidazole H(3)-receptor antagonists of the 2-aminobenzimidazole series 106
Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability 104
Synthesis and characterization of the first inhibitor of: N -acylphosphatidylethanolamine phospholipase D (NAPE-PLD) 104
Design, synthesis and SAR of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors 103
Computer-Aided Design of Novel Antagonists of the EphA2 Receptor 102
Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines 102
Homology models of melatonin receptors: challenges and recent advances. 101
Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. 100
H3-receptor antagonists: Synthesis and structure relationships of para- and meta-substituted 4(5)-phenyl-2-((2-(4(5)-imidazolyl)ethyl)thio)imidazoles 99
Structure-Property Relationships on Histamine H3-Antagonists: Binding of Phenyl-substituted Alkylthioimidazole Derivatives to Rat Plasma Proteins 98
Ligands for the histamine H3-receptor: new potent antagonists of the 2-thioimidazole type 98
In vitro characterization of potency, affinity and selectivity of H3-antagonists: from thioperamide to thioperamide unrelated derivatives 98
Antiproliferative and pro-apoptotic activity of melatonin analogues on melanoma and breast cancer cells 97
Imidazole H3-antagonists: Relationship between Structure and Ex-vivo binding to Rat Brain H3-Receptors 95
ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors 95
Synthesis and Structure-Activity Relationships of FAAH Inhibitors: Cyclohexylcarbamic Acid Biphenyl Esters with Chemical Modulation at the Proximal Phenyl Ring 94
Pharmacological inhibition of FAAH activity in rodents: A promising pharmacological approach for psychological-cardiac comorbidity? 93
Novel melatonin ligands having antidepressant activity as well as sleep-inducing properties 92
Synthesis and characterization of new bivalent agents as melatonin- and histamine h3-ligands. 92
N-(Substituted-anilinoethyl)amides: Design, Synthesis and Pharmacological Characterization of a New Class of Melatonin Receptor Ligands. 92
Totale 13.494
Salva come PNG Salva come JPEG
Categoria #
all - tutte 62.526
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 62.526
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021590 0 0 0 0 0 42 139 35 200 34 97 43
2021/2022759 22 25 13 87 51 19 70 98 51 59 56 208
2022/20232.764 303 265 170 212 275 333 29 157 848 38 92 42
2023/20241.050 58 72 29 37 77 249 74 90 57 76 94 137
2024/20253.696 82 190 244 221 317 384 186 214 491 382 347 638
2025/20264.997 703 922 1.102 806 1.075 389 0 0 0 0 0 0
Totale 17.384